Antibody formulations are described comprising a mixture of an anti-.alpha.4.beta.7 antibody, anantioxidant or chelator, and at least one free amino acid. The disclosedformulations mayhave improved stability, reduced aggregate formation, or both. The presentinvention furtherprovides a safe dosing regimen of these antibody formulations that is easy tofollow, andwhich results in a therapeutically effective amount of the anti-.alpha.4.beta.7 antibody in vivo.